SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is experiencing significant volatility and upward momentum driven by intense short-squeeze dynamics, with investors closely watching a recent SEC filing regarding executive change-of-control agreements as a potential precursor to a buyout. The community is heavily focused on the scarcity of available shares, high borrow rates, and the anticipation of topline results from the Phase 3 REGAL trial for their lead AML immunotherapy.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending following news that the FDA has scheduled an advisory committee meeting for its DMD therapy, a development that triggered short-term volatility as traders de-risked ahead of the upcoming decision date. Despite the market's reaction, the community remains heavily focused on the company's strong five-year clinical data, viewing the meeting as a potential opportunity to secure a broader product label rather than a sign of rejection.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is seeing heavy community debate as investors weigh the stock's multi-year lows against potential catalysts like tariff refunds and an upcoming leadership transition. While some traders are betting on a turnaround ahead of earnings, others remain cautious of structural issues and negative analyst sentiment.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is currently seeing high volatility and intense community discussion as investors weigh promising Ibsrela growth and strong fundamentals against persistent legal and reimbursement headwinds from the CMS bundling dispute. While some shareholders remain bullish on the long-term potential for profitability and acquisition, others are expressing frustration over stagnant price action and the ongoing regulatory uncertainty.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently seeing intense community debate and volatility, driven by ongoing efforts to position its solid oxide fuel cell technology as a critical, on-site energy solution for power-hungry AI data centers. Investors remain sharply divided between those viewing recent pullbacks as a buying opportunity based on long-term AI infrastructure backlogs and those expressing skepticism over the stock's valuation, share dilution, and the competitive threat from other energy alternatives.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending as investors react to a significant strategic agreement with Fit Energy to provide up to 380 megawatts of clean, on-site power for AI data centers. The community remains sharply divided between bulls pointing to the growing proposal pipeline and data center demand, and skeptics who are raising concerns over warrant structures, potential shareholder dilution, and the opacity of the partner involved.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending due to a significant earnings beat and raised full-year revenue guidance that has fueled investor optimism around its QNX software and Physical AI growth potential. Community sentiment is overwhelmingly bullish, with many investors highlighting key partnerships and the upcoming Alloy Kore platform as catalysts for a potential long-term rerating, while actively calling out short-sellers and underestimating analyst targets.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI is experiencing heightened volatility and investor speculation as the market anticipates the potential allocation of FDA priority vouchers following recent executive orders supporting psychedelic therapy. The community is closely monitoring trial milestones for lead assets like BPL-003 and actively debating the stock's valuation disconnect and potential for a strategic partnership or buyout.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending as investors react to a new $6 billion share repurchase program, signaling management's confidence despite ongoing cyclical pressures in automotive and industrial markets. The community remains focused on the stock's potential for a long-term rebound, closely monitoring its performance as it navigates support levels and potential technical breakouts.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as retail investors engage in a heated debate over the company's lack of upward price momentum and delayed relisting plans despite aggressive store expansion and strong operational metrics. The community is actively tracking potential corporate maneuvers, including strategic buybacks and international growth efforts, while speculating on the timing of a return to major exchanges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London PR Newswire CAMBRIDGE, Mass., June 8, 2026 Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for...

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors PR Newswire CAMBRIDGE, Mass., June 3, 2026 CAMBRIDGE, Mass., June 3, 2026...

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV Candidate into the Clinic

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV Candidate into the Clinic Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV Candidate into the Clinic PR Newswire CAMBRIDGE, Mass., June 1, 2026 Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new...

Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board

Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board PR Newswire NEW YORK and CAMBRIDGE, Mass., May 26, 2026 Appointment deepens...

Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston

Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston PR Newswire CAMBRIDGE, Mass., April 27...

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline Decoy Therapeutics...

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 PR Newswire CAMBRIDGE, Mass. and HOUSTON, April 6, 2026 Live video webcast...

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 /PRNewswire/ --Decoy Therapeutics, Inc...

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform Decoy Therapeutics Enters Strategic...

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split Decoy Therapeutics Announces 1-for-12 Reverse Stock Split PR Newswire CAMBRIDGE, Mass., March 5, 2026 CAMBRIDGE, Mass., March 5, 2026...

Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. It engages in leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company was founded by Frederick E. Pierce, Barbara Hibner, Peter Marschel, Michael Lipp, and Jodi Cooper in 2020 and is headquartered in Houston, TX.

Decoy Therapeutics Inc.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.02
Prev Close	$5.92
Open	$5.86
Dividend Yield	0.00%
50-Day Moving Average	$6.11
Beta	0.09
Avg. Volume	11,444.42
PE Ratio	-0.05

52-Week High	$415.80
52-Week Low	$4.32
Market Capitalization	$3.15M
EPS (Annual)	-$129.10
Price to Book	0.81
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

DCOYDecoy Therapeutics Inc.

Latest DCOY News